Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14996486 | 0.85 | AVPR1A (0.50) | AVPR1A | |
| SCHEMBL13168272 | 0.83 | AVPR1A (0.45) | AVPR1A | |
| SCHEMBL2514268 | 0.82 | SIGMAR1 (0.59) | SIGMAR1 | |
| SCHEMBL2755063 | 0.81 | AVPR1A (0.47) | AVPR1A | |
| SCHEMBL8014953 | 0.80 | SIGMAR1 (0.63) | SIGMAR1 | |
| SCHEMBL13519263 | 0.78 | AVPR1A (0.41) | AVPR1ASIGMAR1 | |
| SCHEMBL30447448 | 0.77 | AVPR1A (0.42) | AVPR1ASIGMAR1CCNCCDK8HASPIN | |
| SCHEMBL13366438 | 0.75 | SIGMAR1 (0.57) | SIGMAR1 | |
| SCHEMBL13366939 | 0.75 | SIGMAR1 (0.57) | SIGMAR1 | |
| SCHEMBL485825 | 0.75 | AVPR1A (0.43) | AVPR1ACCNCCDK8HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3R5 | AVPR1A 4861/4885SIGMAR1 4422/4885CCNC 285/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | AVPR1A 22/4885SIGMAR1 572/4885CCNC 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.